Shinya Yamanaka

Yamanaka has a clear translational regenerative-medicine vision around iPS cells, including clinical applications, disease modeling, stem cell therapy, and potentially inexhaustible cell-derived products. However, the provided evidence does not show that he publicly articulated a concrete, durable vision specifically for ending aging, reversing organism-level biological decline, or materially extending healthy human lifespan. The aging connection is present mainly as a research application and mechanistic implication, not as a direct longevity vision.

The dimension applies: the evidence shows primary academic authorship in embryonic stem cell and induced pluripotent stem cell biology, including work on developmental potency mapping, iPS-derived endothelial cells, and SIRT1 regulation during reprogramming. However, no citation metrics are provided, and the supplied papers do not include clear citation-weighted evidence of field-defining impact, so the score should not rely on Yamanaka's broader reputation.

There is limited evidence of institution-building involvement through leadership at CiRA/CiRA Foundation, but no disclosed investments, donations, personal capital deployment, fund allocation amounts, or independently corroborated catalytic funding activity. This supports only a low score for capital deployed, with low confidence.

Strategic taste applies because Yamanaka made a field-defining scientific choice around cellular reprogramming that opened major paths for regenerative medicine and aging-relevant research. The evidence supports strong counterfactual importance of the iPS/Yamanaka-factor work, but it does not document an explicit strategy thesis, early contrarian reasoning, funding bets, stage preference, or a broader pattern of thesis-driven deployment choices.

Yamanaka has strong field-creation evidence through the creation of the iPSC/Yamanaka-factor reprogramming category and protocol, which independent sources describe as broadly enabling new models, regenerative medicine, drug discovery, and cellular aging research. However, the supplied evidence does not show founded organizations, donation-created programs, or funding paths.

The dimension applies, but the provided evidence contains almost no direct indicators of public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, or personal skin in the game. Yamanaka's iPSC discovery was highly consequential and later Nobel-recognized, but scientific importance alone does not establish bravery_conviction under this rubric. A low score is warranted because there is some implicit research conviction in pioneering iPSC work, but the evidence supplied does not document public or personal risk.

Yamanaka shows credible multiplier-effect evidence through the iPSC discovery’s broad follow-on impact across pharmaceutical, clinical, laboratory, regenerative-medicine, cancer, epigenetics, and aging research. The provided evidence also indicates institutional leadership roles at CiRA/CiRA Foundation and advisory roles, but these are from an unknown-independence dossier item and cannot strongly raise the score by themselves. Evidence for capital attraction, founded organizations, policy attention, or documented talent/founder networks is absent.